1
|
Kober C, Roewe J, Schmees N, Roese L, Roehn U, Bader B, Stoeckigt D, Prinz F, Gorjánácz M, Roider HG, Olesch C, Leder G, Irlbacher H, Lesche R, Lefranc J, Oezcan-Wahlbrink M, Batra AS, Elmadany N, Carretero R, Sahm K, Oezen I, Cichon F, Baumann D, Sadik A, Opitz CA, Weinmann H, Hartung IV, Kreft B, Offringa R, Platten M, Gutcher I. Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy. J Immunother Cancer 2023; 11:e007495. [PMID: 37963637 PMCID: PMC10649913 DOI: 10.1136/jitc-2023-007495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/08/2023] [Indexed: 11/16/2023] Open
Abstract
BACKGROUND The metabolism of tryptophan to kynurenines (KYN) by indoleamine-2,3-dioxygenase or tryptophan-2,3-dioxygenase is a key pathway of constitutive and adaptive tumor immune resistance. The immunosuppressive effects of KYN in the tumor microenvironment are predominantly mediated by the aryl hydrocarbon receptor (AhR), a cytosolic transcription factor that broadly suppresses immune cell function. Inhibition of AhR thus offers an antitumor therapy opportunity via restoration of immune system functions. METHODS The expression of AhR was evaluated in tissue microarrays of head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). A structure class of inhibitors that block AhR activation by exogenous and endogenous ligands was identified, and further optimized, using a cellular screening cascade. The antagonistic properties of the selected AhR inhibitor candidate BAY 2416964 were determined using transactivation assays. Nuclear translocation, target engagement and the effect of BAY 2416964 on agonist-induced AhR activation were assessed in human and mouse cancer cells. The immunostimulatory properties on gene and cytokine expression were examined in human immune cell subsets. The in vivo efficacy of BAY 2416964 was tested in the syngeneic ovalbumin-expressing B16F10 melanoma model in mice. Coculture of human H1299 NSCLC cells, primary peripheral blood mononuclear cells and fibroblasts mimicking the human stromal-tumor microenvironment was used to assess the effects of AhR inhibition on human immune cells. Furthermore, tumor spheroids cocultured with tumor antigen-specific MART-1 T cells were used to study the antigen-specific cytotoxic T cell responses. The data were analyzed statistically using linear models. RESULTS AhR expression was observed in tumor cells and tumor-infiltrating immune cells in HNSCC, NSCLC and CRC. BAY 2416964 potently and selectively inhibited AhR activation induced by either exogenous or endogenous AhR ligands. In vitro, BAY 2416964 restored immune cell function in human and mouse cells, and furthermore enhanced antigen-specific cytotoxic T cell responses and killing of tumor spheroids. In vivo, oral application with BAY 2416964 was well tolerated, induced a proinflammatory tumor microenvironment, and demonstrated antitumor efficacy in a syngeneic cancer model in mice. CONCLUSIONS These findings identify AhR inhibition as a novel therapeutic approach to overcome immune resistance in various types of cancers.
Collapse
Affiliation(s)
- Christina Kober
- Bayer AG, Pharmaceutical Division, Berlin, Germany
- DKFZ-Bayer Joint Immunotherapy Laboratory (D220), DKFZ-Bayer Joint Immunotherapy Laboratory, Heidelberg, Germany
| | - Julian Roewe
- German Cancer Consortium (DKTK), Clinical Cooperation Unit (CCU), Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany
- Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Heidelberg, Germany
| | | | - Lars Roese
- Bayer AG, Pharmaceutical Division, Berlin, Germany
| | - Ulrike Roehn
- Bayer AG, Pharmaceutical Division, Berlin, Germany
| | | | | | | | | | | | - Catherine Olesch
- Bayer AG, Pharmaceutical Division, Berlin, Germany
- DKFZ-Bayer Joint Immunotherapy Laboratory (D220), DKFZ-Bayer Joint Immunotherapy Laboratory, Heidelberg, Germany
| | | | | | - Ralf Lesche
- Bayer AG, Pharmaceutical Division, Berlin, Germany
| | | | - Mine Oezcan-Wahlbrink
- Bayer AG, Pharmaceutical Division, Berlin, Germany
- DKFZ-Bayer Joint Immunotherapy Laboratory (D220), DKFZ-Bayer Joint Immunotherapy Laboratory, Heidelberg, Germany
| | - Ankita Sati Batra
- German Cancer Consortium (DKTK), Clinical Cooperation Unit (CCU), Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany
- Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Heidelberg, Germany
| | - Nirmeen Elmadany
- German Cancer Consortium (DKTK), Clinical Cooperation Unit (CCU), Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany
- Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Heidelberg, Germany
| | - Rafael Carretero
- Bayer AG, Pharmaceutical Division, Berlin, Germany
- DKFZ-Bayer Joint Immunotherapy Laboratory (D220), DKFZ-Bayer Joint Immunotherapy Laboratory, Heidelberg, Germany
| | - Katharina Sahm
- German Cancer Consortium (DKTK), Clinical Cooperation Unit (CCU), Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany
- Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Heidelberg, Germany
| | - Iris Oezen
- German Cancer Consortium (DKTK), Clinical Cooperation Unit (CCU), Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany
| | - Frederik Cichon
- German Cancer Consortium (DKTK), Clinical Cooperation Unit (CCU), Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany
| | - Daniel Baumann
- DKFZ-Bayer Joint Immunotherapy Laboratory (D220), DKFZ-Bayer Joint Immunotherapy Laboratory, Heidelberg, Germany
| | - Ahmed Sadik
- Brain Cancer Metabolism (B350), German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Christiane A Opitz
- Brain Cancer Metabolism (B350), German Cancer Research Center (DKFZ), Heidelberg, Germany
| | | | | | | | - Rienk Offringa
- DKFZ-Bayer Joint Immunotherapy Laboratory (D220), DKFZ-Bayer Joint Immunotherapy Laboratory, Heidelberg, Germany
- Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
| | - Michael Platten
- German Cancer Consortium (DKTK), Clinical Cooperation Unit (CCU), Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Heidelberg, Germany
- Department of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Heidelberg, Germany
| | | |
Collapse
|
2
|
Doijad SP, Gisch N, Frantz R, Kumbhar BV, Falgenhauer J, Imirzalioglu C, Falgenhauer L, Mischnik A, Rupp J, Behnke M, Buhl M, Eisenbeis S, Gastmeier P, Gölz H, Häcker GA, Käding N, Kern WV, Kola A, Kramme E, Peter S, Rohde AM, Seifert H, Tacconelli E, Vehreschild MJGT, Walker SV, Zweigner J, Schwudke D, Chakraborty T, Thoma N, Weber A, Vavra M, Schuster S, Peyerl-Hoffmann G, Hamprecht A, Proske S, Stelzer Y, Wille J, Lenke D, Bader B, Dinkelacker A, Hölzl F, Kunstle L, Chakraborty T. Resolving colistin resistance and heteroresistance in Enterobacter species. Nat Commun 2023; 14:140. [PMID: 36627272 PMCID: PMC9832134 DOI: 10.1038/s41467-022-35717-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2022] [Accepted: 12/16/2022] [Indexed: 01/11/2023] Open
Abstract
Species within the Enterobacter cloacae complex (ECC) include globally important nosocomial pathogens. A three-year study of ECC in Germany identified Enterobacter xiangfangensis as the most common species (65.5%) detected, a result replicated by examining a global pool of 3246 isolates. Antibiotic resistance profiling revealed widespread resistance and heteroresistance to the antibiotic colistin and detected the mobile colistin resistance (mcr)-9 gene in 19.2% of all isolates. We show that resistance and heteroresistance properties depend on the chromosomal arnBCADTEF gene cassette whose products catalyze transfer of L-Ara4N to lipid A. Using comparative genomics, mutational analysis, and quantitative lipid A profiling we demonstrate that intrinsic lipid A modification levels are genospecies-dependent and governed by allelic variations in phoPQ and mgrB, that encode a two-component sensor-activator system and specific inhibitor peptide. By generating phoPQ chimeras and combining them with mgrB alleles, we show that interactions at the pH-sensing interface of the sensory histidine kinase phoQ dictate arnBCADTEF expression levels. To minimize therapeutic failures, we developed an assay that accurately detects colistin resistance levels for any ECC isolate.
Collapse
Affiliation(s)
- Swapnil Prakash Doijad
- German Center for Infection Research (DZIF), Braunschweig, Germany.,Institute of Medical Microbiology, Justus Liebig University, Gießen, Germany
| | - Nicolas Gisch
- Division of Bioanalytical Chemistry, Priority Area Infections, Research Center Borstel, Leibniz Lung Center, Borstel, Germany
| | - Renate Frantz
- German Center for Infection Research (DZIF), Braunschweig, Germany.,Institute of Medical Microbiology, Justus Liebig University, Gießen, Germany
| | - Bajarang Vasant Kumbhar
- Department of Biological Sciences, Sunandan Divatia School of Science, NMIMS (Deemed-to-be) University, Vile Parle, Mumbai, India
| | - Jane Falgenhauer
- German Center for Infection Research (DZIF), Braunschweig, Germany.,Institute of Medical Microbiology, Justus Liebig University, Gießen, Germany
| | - Can Imirzalioglu
- German Center for Infection Research (DZIF), Braunschweig, Germany.,Institute of Medical Microbiology, Justus Liebig University, Gießen, Germany
| | - Linda Falgenhauer
- German Center for Infection Research (DZIF), Braunschweig, Germany.,Institute of Medical Microbiology, Justus Liebig University, Gießen, Germany.,Institute of Hygiene and Environmental Medicine, Justus Liebig University, Gießen, Germany
| | - Alexander Mischnik
- German Center for Infection Research (DZIF), Braunschweig, Germany.,Department of Infectious Diseases and Microbiology, University of Lübeck, Lübeck, Germany
| | - Jan Rupp
- German Center for Infection Research (DZIF), Braunschweig, Germany.,Department of Infectious Diseases and Microbiology, University of Lübeck, Lübeck, Germany
| | - Michael Behnke
- German Center for Infection Research (DZIF), Braunschweig, Germany.,Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität of Berlin and Berlin Institute of Health, Institute of Hygiene and Environmental Medicine, Berlin, Germany
| | - Michael Buhl
- German Center for Infection Research (DZIF), Braunschweig, Germany.,Institute of Medical Microbiology and Hygiene, Tübingen University, Tübingen, Germany.,Division of Infectious Diseases, Department of Internal Medicine I, Tübingen University, Tübingen, Germany.,Institute of Clinical Hygiene, Medical Microbiology and Infectiology, Paracelsus Medical University, Klinikum Nürnberg, Nürnberg, Germany
| | - Simone Eisenbeis
- German Center for Infection Research (DZIF), Braunschweig, Germany.,Division of Infectious Diseases, Department of Internal Medicine I, Tübingen University, Tübingen, Germany
| | - Petra Gastmeier
- German Center for Infection Research (DZIF), Braunschweig, Germany.,Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität of Berlin and Berlin Institute of Health, Institute of Hygiene and Environmental Medicine, Berlin, Germany
| | - Hanna Gölz
- German Center for Infection Research (DZIF), Braunschweig, Germany.,Institute for Medical Microbiology and Hygiene, Albert-Ludwigs-University, Freiburg, Germany
| | - Georg Alexander Häcker
- German Center for Infection Research (DZIF), Braunschweig, Germany.,Institute for Medical Microbiology and Hygiene, Albert-Ludwigs-University, Freiburg, Germany
| | - Nadja Käding
- German Center for Infection Research (DZIF), Braunschweig, Germany.,Department of Infectious Diseases and Microbiology, University of Lübeck, Lübeck, Germany
| | - Winfried V Kern
- German Center for Infection Research (DZIF), Braunschweig, Germany.,Division of Infectious Diseases, Department of Medicine II, Faculty of Medicine and University Hospital and Medical Center, Albert-Ludwigs-University, Freiburg, Germany
| | - Axel Kola
- German Center for Infection Research (DZIF), Braunschweig, Germany.,Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität of Berlin and Berlin Institute of Health, Institute of Hygiene and Environmental Medicine, Berlin, Germany
| | - Evelyn Kramme
- Department of Infectious Diseases and Microbiology, University of Lübeck, Lübeck, Germany.,Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität of Berlin and Berlin Institute of Health, Institute of Hygiene and Environmental Medicine, Berlin, Germany
| | - Silke Peter
- German Center for Infection Research (DZIF), Braunschweig, Germany.,Institute of Medical Microbiology and Hygiene, Tübingen University, Tübingen, Germany
| | - Anna M Rohde
- German Center for Infection Research (DZIF), Braunschweig, Germany.,Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität of Berlin and Berlin Institute of Health, Institute of Hygiene and Environmental Medicine, Berlin, Germany
| | - Harald Seifert
- German Center for Infection Research (DZIF), Braunschweig, Germany.,Institute for Medical Microbiology, Immunology, and Hygiene, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Evelina Tacconelli
- German Center for Infection Research (DZIF), Braunschweig, Germany.,Division of Infectious Diseases, Department of Internal Medicine I, Tübingen University, Tübingen, Germany
| | - Maria J G T Vehreschild
- German Center for Infection Research (DZIF), Braunschweig, Germany.,Department I of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.,Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany
| | - Sarah V Walker
- German Center for Infection Research (DZIF), Braunschweig, Germany.,Institute for Medical Microbiology, Immunology, and Hygiene, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Janine Zweigner
- German Center for Infection Research (DZIF), Braunschweig, Germany.,Institute for Medical Microbiology, Immunology, and Hygiene, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
| | - Dominik Schwudke
- German Center for Infection Research (DZIF), Braunschweig, Germany.,Division of Bioanalytical Chemistry, Priority Area Infections, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.,Airway Research Center North, Member of the German Center for Lung Research (DZL), Site: Research Center Borstel, Borstel, Germany
| | | | - Trinad Chakraborty
- German Center for Infection Research (DZIF), Braunschweig, Germany. .,Institute of Medical Microbiology, Justus Liebig University, Gießen, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Zablowsky N, Farack L, Rofall S, Kramer J, Meyer H, Nguyen D, Ulrich AKC, Bader B, Steigemann P. High Throughput FISH Screening Identifies Small Molecules That Modulate Oncogenic lncRNA MALAT1 via GSK3B and hnRNPs. Noncoding RNA 2023; 9:ncrna9010002. [PMID: 36649031 PMCID: PMC9844399 DOI: 10.3390/ncrna9010002] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2022] [Revised: 12/12/2022] [Accepted: 12/20/2022] [Indexed: 01/06/2023] Open
Abstract
Traditionally, small molecule-based drug discovery has mainly focused on proteins as the drug target. Opening RNA as an additional target space for small molecules offers the possibility to therapeutically modulate disease-driving non-coding RNA targets as well as mRNA of otherwise undruggable protein targets. MALAT1 is a highly conserved long-noncoding RNA whose overexpression correlates with poor overall patient survival in some cancers. We report here a fluorescence in-situ hybridization-based high-content imaging screen to identify small molecules that modulate the oncogenic lncRNA MALAT1 in a cellular setting. From a library of FDA approved drugs and known bioactive molecules, we identified two compounds, including Niclosamide, an FDA-approved drug, that lead to a rapid decrease of MALAT1 nuclear levels with good potency. Mode-of-action studies suggest a novel cellular regulatory pathway that impacts MALAT1 lncRNA nuclear levels by GSK3B activation and the involvement of the RNA modulating family of heterogenous nuclear ribonucleoproteins (hnRNPs). This study is the basis for the identification of novel targets that lead to a reduction of the oncogenic lncRNA MALAT1 in a cancer setting.
Collapse
|
4
|
Bader B, Gielnik MM, Bledow R. How transformational leadership transforms followers’ affect and work engagement. European Journal of Work and Organizational Psychology 2022. [DOI: 10.1080/1359432x.2022.2161368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
- Benjamin Bader
- Work and Organisation Subject Group, Newcastle University Business School Leadership, Newcastle Upon Tyne, UK
| | - Michael M. Gielnik
- Institute of Management & Organization, Leuphana University Lüneburg, Lüneburg, Germany
| | - Ronald Bledow
- Organisational Behaviour & Human Resources, Singapore Management University, Singapore
| |
Collapse
|
5
|
Schuster T, Bader AK, Bader B, Rousseau DM. Does what happens abroad stay abroad? Displaced aggression and emotional regulation in expatriate psychological contracts. J Occupat & Organ Psyc 2022. [DOI: 10.1111/joop.12405] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Tassilo Schuster
- University of Bamberg/Fraunhofer Institute for Integrated Circuits IIS Nuernberg Germany
| | | | - Benjamin Bader
- Newcastle University Business School Newcastle upon Tyne UK
| | | |
Collapse
|
6
|
Bader B. [80/m-Difficult-to-control arterial hypertension and hypokalemia : Preparation for the medical specialist examination: part 132]. Internist (Berl) 2022; 63:180-185. [PMID: 35303129 DOI: 10.1007/s00108-022-01304-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/10/2022] [Indexed: 11/29/2022]
Affiliation(s)
- B Bader
- Medizinische Klinik II (Nephrologie und Intensivmedizin), St. Joseph Krankenhaus Berlin-Tempelhof GmbH, Wüsthoffstr. 15, 12101, Berlin, Deutschland. .,DaVita MVZ Elsterland, Frankfurter Str. 16b, 04916, Herzberg, Deutschland. .,DaVita MVZ Nierenzentrum Berlin-Britz, Britzer Damm 185, 12347, Berlin, Deutschland.
| |
Collapse
|
7
|
Abstract
RAS proteins play major roles in many human cancers, but programs to develop direct RAS inhibitors so far have only been successful for the oncogenic KRAS mutant G12C. As an alternative approach, inhibitors for the RAS guanine nucleotide exchange factor SOS1 have been investigated by several academic groups and companies, and major progress has been achieved in recent years in the optimization of small molecule activators and inhibitors of SOS1. Here, we review the discovery and development of small molecule modulators of SOS1 and their molecular binding modes and modes of action. As targeting the RAS pathway is expected to result in the development of resistance mechanisms, SOS1 inhibitors will most likely be best applied in vertical combination approaches where two nodes of the RAS signaling pathway are hit simultaneously. We summarize the current understanding of which combination partners may be most beneficial for patients with RAS driven tumors.
Collapse
Affiliation(s)
| | - Benjamin Bader
- Screening, Lead Discovery, Nuvisan ICB GmbH, Berlin, Germany
| |
Collapse
|
8
|
Bader B. [79/f-Somnolence, hypernatremia and acute kidney injury during treatment with lithium : Preparation for the medical specialist examination: part 104]. Internist (Berl) 2022; 63:21-26. [PMID: 35029700 DOI: 10.1007/s00108-021-01240-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/13/2021] [Indexed: 11/25/2022]
Affiliation(s)
- B Bader
- Medizinische Klinik II (Nephrologie und Intensivmedizin), St. Joseph Krankenhaus Berlin-Tempelhof GmbH, Wüsthoffstraße 15, 12101, Berlin, Deutschland.
- DaVita MVZ Elsterland, Frankfurter Straße 16b, 04916, Herzberg, Deutschland.
- DaVita MVZ Nierenzentrum Berlin-Britz, Britzer Damm 185, 12347, Berlin, Deutschland.
| |
Collapse
|
9
|
Schloemer-Jarvis A, Bader B, Böhm SA. The role of human resource practices for including persons with disabilities in the workforce: a systematic literature review. The International Journal of Human Resource Management 2021. [DOI: 10.1080/09585192.2021.1996433] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Affiliation(s)
| | - Benjamin Bader
- Leadership, Work and Organisation Subject Group, Newcastle University Business School, Newcastle upon Tyne, UK
| | - Stephan A. Böhm
- Center for Disability and Integration (CDI-HSG), University of St. Gallen, St. Gallen, Switzerland
| |
Collapse
|
10
|
Berger M, Wortmann L, Buchgraber P, Lücking U, Zitzmann-Kolbe S, Wengner AM, Bader B, Bömer U, Briem H, Eis K, Rehwinkel H, Bartels F, Moosmayer D, Eberspächer U, Lienau P, Hammer S, Schatz CA, Wang Q, Wang Q, Mumberg D, Nising CF, Siemeister G. BAY-8400: A Novel Potent and Selective DNA-PK Inhibitor which Shows Synergistic Efficacy in Combination with Targeted Alpha Therapies. J Med Chem 2021; 64:12723-12737. [PMID: 34428039 DOI: 10.1021/acs.jmedchem.1c00762] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Eukaryotes have evolved two major pathways to repair potentially lethal DNA double-strand breaks. Homologous recombination represents a precise, DNA-template-based mechanism available during the S and G2 cell cycle phase, whereas non-homologous end joining, which requires DNA-dependent protein kinase (DNA-PK), allows for fast, cell cycle-independent but less accurate DNA repair. Here, we report the discovery of BAY-8400, a novel selective inhibitor of DNA-PK. Starting from a triazoloquinoxaline, which had been identified as a hit from a screen for ataxia telangiectasia and Rad3-related protein (ATR) inhibitors with inhibitory activity against ATR, ATM, and DNA-PK, lead optimization efforts focusing on potency and selectivity led to the discovery of BAY-8400. In in vitro studies, BAY-8400 showed synergistic activity of DNA-PK inhibition with DNA damage-inducing targeted alpha therapy. Combination of PSMA-targeted thorium-227 conjugate BAY 2315497 treatment of human prostate tumor-bearing mice with BAY-8400 oral treatment increased antitumor efficacy, as compared to PSMA-targeted thorium-227 conjugate monotherapy.
Collapse
Affiliation(s)
- Markus Berger
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Lars Wortmann
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Philipp Buchgraber
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Ulrich Lücking
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | | | - Antje M Wengner
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Benjamin Bader
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Ulf Bömer
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Hans Briem
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Knut Eis
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Hartmut Rehwinkel
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Florian Bartels
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Dieter Moosmayer
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Uwe Eberspächer
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Philip Lienau
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Stefanie Hammer
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Christoph A Schatz
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Qiuwen Wang
- Pharmaron Beijing Co., Ltd., 6 Taihe Road, BDA, Beijing 100176, P. R. China
| | - Qi Wang
- WuXi AppTec (Wuhan) Co., Ltd., 666 Gaoxin Road, East Lake High-tech Development Zone, Wuhan 430075, P. R. China
| | - Dominik Mumberg
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Carl F Nising
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| | - Gerhard Siemeister
- Research & Development, Pharmaceuticals, Bayer AG, Berlin 13353, Germany
| |
Collapse
|
11
|
Bader AK, Bader B, Froese FJ, Sekiguchi T. One way or another? An international comparison of expatriate performance management in multinational companies. Hum Resour Manage 2021. [DOI: 10.1002/hrm.22065] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
12
|
Lemos C, Schulze VK, Baumgart SJ, Nevedomskaya E, Heinrich T, Lefranc J, Bader B, Christ CD, Briem H, Kuhnke LP, Holton SJ, Bömer U, Lienau P, von Nussbaum F, Nising CF, Bauser M, Hägebarth A, Mumberg D, Haendler B. The potent AMPK inhibitor BAY-3827 shows strong efficacy in androgen-dependent prostate cancer models. Cell Oncol (Dordr) 2021; 44:581-594. [PMID: 33492659 DOI: 10.1007/s13402-020-00584-8] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/16/2020] [Indexed: 12/14/2022] Open
Abstract
PURPOSE 5' adenosine monophosphate-activated kinase (AMPK) is an essential regulator of cellular energy homeostasis and has been associated with different pathologies, including cancer. Precisely defining the biological role of AMPK necessitates the availability of a potent and selective inhibitor. METHODS High-throughput screening and chemical optimization were performed to identify a novel AMPK inhibitor. Cell proliferation and mechanistic assays, as well as gene expression analysis and chromatin immunoprecipitation were used to investigate the cellular impact as well as the crosstalk between lipid metabolism and androgen signaling in prostate cancer models. Also, fatty acid turnover was determined by examining lipid droplet formation. RESULTS We identified BAY-3827 as a novel and potent AMPK inhibitor with additional activity against ribosomal 6 kinase (RSK) family members. It displays strong anti-proliferative effects in androgen-dependent prostate cancer cell lines. Analysis of genes involved in AMPK signaling revealed that the expression of those encoding 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR), fatty acid synthase (FASN) and 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 (PFKFB2), all of which are involved in lipid metabolism, was strongly upregulated by androgen in responsive models. Chromatin immunoprecipitation DNA-sequencing (ChIP-seq) analysis identified several androgen receptor (AR) binding peaks in the HMGCR and PFKFB2 genes. BAY-3827 strongly down-regulated the expression of lipase E (LIPE), cAMP-dependent protein kinase type II-beta regulatory subunit (PRKAR2B) and serine-threonine kinase AKT3 in responsive prostate cancer cell lines. Also, the expression of members of the carnitine palmitoyl-transferase 1 (CPT1) family was inhibited by BAY-3827, and this was paralleled by impaired lipid flux. CONCLUSIONS The availability of the potent inhibitor BAY-3827 will contribute to a better understanding of the role of AMPK signaling in cancer, especially in prostate cancer.
Collapse
Affiliation(s)
- Clara Lemos
- Bayer AG, Research and Development, Pharmaceuticals, Berlin, Germany
| | - Volker K Schulze
- Bayer AG, Research and Development, Pharmaceuticals, Berlin, Germany
| | - Simon J Baumgart
- Bayer AG, Research and Development, Pharmaceuticals, Berlin, Germany.,Bayer US LLC, Cambridge, MA, USA
| | | | - Tobias Heinrich
- Bayer AG, Research and Development, Pharmaceuticals, Berlin, Germany
| | - Julien Lefranc
- Bayer AG, Research and Development, Pharmaceuticals, Berlin, Germany.,Nuvisan Innovation Campus Berlin, Berlin, Germany
| | - Benjamin Bader
- Bayer AG, Research and Development, Pharmaceuticals, Berlin, Germany.,Nuvisan Innovation Campus Berlin, Berlin, Germany
| | - Clara D Christ
- Bayer AG, Research and Development, Pharmaceuticals, Berlin, Germany
| | - Hans Briem
- Bayer AG, Research and Development, Pharmaceuticals, Berlin, Germany
| | - Lara P Kuhnke
- Bayer AG, Research and Development, Pharmaceuticals, Berlin, Germany
| | - Simon J Holton
- Bayer AG, Research and Development, Pharmaceuticals, Berlin, Germany.,Nuvisan Innovation Campus Berlin, Berlin, Germany
| | - Ulf Bömer
- Bayer AG, Research and Development, Pharmaceuticals, Berlin, Germany.,Nuvisan Innovation Campus Berlin, Berlin, Germany
| | - Philip Lienau
- Bayer AG, Research and Development, Pharmaceuticals, Berlin, Germany
| | - Franz von Nussbaum
- Bayer AG, Research and Development, Pharmaceuticals, Berlin, Germany.,Nuvisan Innovation Campus Berlin, Berlin, Germany
| | - Carl F Nising
- Bayer AG, Research and Development, Pharmaceuticals, Berlin, Germany
| | - Marcus Bauser
- Bayer AG, Research and Development, Pharmaceuticals, Berlin, Germany.,Janssen Pharmaceuticals, Beerse, Belgium
| | - Andrea Hägebarth
- Bayer AG, Research and Development, Pharmaceuticals, Berlin, Germany
| | - Dominik Mumberg
- Bayer AG, Research and Development, Pharmaceuticals, Berlin, Germany
| | - Bernard Haendler
- Bayer AG, Research and Development, Pharmaceuticals, Berlin, Germany.
| |
Collapse
|
13
|
Naujoks J, Potze L, Kuehnlenz J, Kamburov A, Nevedomskaya E, Steffen A, Luther C, Anurin A, Buttgereit A, Prechtl S, Bader B, Lesche R, Staller P, Lange M, Nicke B. Abstract A29: Genome-wide CRISPR/Cas9 screens for the identification of novel YAP1/TAZ modulators. Mol Cancer Res 2020. [DOI: 10.1158/1557-3125.hippo19-a29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Aberrant activation of the Hippo pathway effectors YAP1/TAZ promotes cell proliferation and tumorigenesis. To identify novel regulators of YAP1/TAZ in cancer, we established a FACS-based screening system monitoring YAP1/TAZ activity in MDA-MB-231 breast cancer cells. Using these cells, we performed pooled genome-wide CRISPR/Cas9 knockout and CRISPR activation/interference (a/i) screens. The list of hits included previously known YAP1/TAZ modulators such as LATS2, AJUBA, and TAZ itself, demonstrating the robustness of the screen. Moreover, we identified about 30 novel candidate genes with potential inhibitory activity on YAP1/TAZ and about 50 candidate genes that may play a role in YAP1/TAZ activation. These genes represent diverse cellular functions such as regulation of actin cytoskeleton, integrin signaling, and ER protein processing, among others. Modulation of endogenous YAP1/TAZ target genes was assessed by individual gene knockout using crRNAs. Functional characterization of the novel potential YAP1/TAZ modulators will aid to the further understanding of YAP1/TAZ biology in health and disease.
Citation Format: Jan Naujoks, Lisette Potze, Julia Kuehnlenz, Atanas Kamburov, Ekaterina Nevedomskaya, Andreas Steffen, Claudia Luther, Anna Anurin, Anne Buttgereit, Stefan Prechtl, Benjamin Bader, Ralf Lesche, Peter Staller, Martin Lange, Barbara Nicke. Genome-wide CRISPR/Cas9 screens for the identification of novel YAP1/TAZ modulators [abstract]. In: Proceedings of the AACR Special Conference on the Hippo Pathway: Signaling, Cancer, and Beyond; 2019 May 8-11; San Diego, CA. Philadelphia (PA): AACR; Mol Cancer Res 2020;18(8_Suppl):Abstract nr A29.
Collapse
Affiliation(s)
- Jan Naujoks
- Bayer AG, Research & Development, Pharmaceuticals Division, Berlin, Germany
| | - Lisette Potze
- Bayer AG, Research & Development, Pharmaceuticals Division, Berlin, Germany
| | - Julia Kuehnlenz
- Bayer AG, Research & Development, Pharmaceuticals Division, Berlin, Germany
| | - Atanas Kamburov
- Bayer AG, Research & Development, Pharmaceuticals Division, Berlin, Germany
| | | | - Andreas Steffen
- Bayer AG, Research & Development, Pharmaceuticals Division, Berlin, Germany
| | - Claudia Luther
- Bayer AG, Research & Development, Pharmaceuticals Division, Berlin, Germany
| | - Anna Anurin
- Bayer AG, Research & Development, Pharmaceuticals Division, Berlin, Germany
| | - Anne Buttgereit
- Bayer AG, Research & Development, Pharmaceuticals Division, Berlin, Germany
| | - Stefan Prechtl
- Bayer AG, Research & Development, Pharmaceuticals Division, Berlin, Germany
| | - Benjamin Bader
- Bayer AG, Research & Development, Pharmaceuticals Division, Berlin, Germany
| | - Ralf Lesche
- Bayer AG, Research & Development, Pharmaceuticals Division, Berlin, Germany
| | - Peter Staller
- Bayer AG, Research & Development, Pharmaceuticals Division, Berlin, Germany
| | - Martin Lange
- Bayer AG, Research & Development, Pharmaceuticals Division, Berlin, Germany
| | - Barbara Nicke
- Bayer AG, Research & Development, Pharmaceuticals Division, Berlin, Germany
| |
Collapse
|
14
|
Lücking U, Wortmann L, Wengner AM, Lefranc J, Lienau P, Briem H, Siemeister G, Bömer U, Denner K, Schäfer M, Koppitz M, Eis K, Bartels F, Bader B, Bone W, Moosmayer D, Holton SJ, Eberspächer U, Grudzinska-Goebel J, Schatz C, Deeg G, Mumberg D, von Nussbaum F. Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models. J Med Chem 2020; 63:7293-7325. [PMID: 32502336 DOI: 10.1021/acs.jmedchem.0c00369] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
The ATR kinase plays a key role in the DNA damage response by activating essential signaling pathways of DNA damage repair, especially in response to replication stress. Because DNA damage and replication stress are major sources of genomic instability, selective ATR inhibition has been recognized as a promising new approach in cancer therapy. We now report the identification and preclinical evaluation of the novel, clinical ATR inhibitor BAY 1895344. Starting from quinoline 2 with weak ATR inhibitory activity, lead optimization efforts focusing on potency, selectivity, and oral bioavailability led to the discovery of the potent, highly selective, orally available ATR inhibitor BAY 1895344, which exhibited strong monotherapy efficacy in cancer xenograft models that carry certain DNA damage repair deficiencies. Moreover, combination treatment of BAY 1895344 with certain DNA damage inducing chemotherapy resulted in synergistic antitumor activity. BAY 1895344 is currently under clinical investigation in patients with advanced solid tumors and lymphomas (NCT03188965).
Collapse
Affiliation(s)
- Ulrich Lücking
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Lars Wortmann
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Antje M Wengner
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Julien Lefranc
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Philip Lienau
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Hans Briem
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Gerhard Siemeister
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Ulf Bömer
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Karsten Denner
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Martina Schäfer
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Marcus Koppitz
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Knut Eis
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Florian Bartels
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Benjamin Bader
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Wilhelm Bone
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Dieter Moosmayer
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Simon J Holton
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Uwe Eberspächer
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | | | - Christoph Schatz
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Gesa Deeg
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Dominik Mumberg
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Franz von Nussbaum
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| |
Collapse
|
15
|
Mortier J, Friberg A, Badock V, Moosmayer D, Schroeder J, Steigemann P, Siegel F, Gradl S, Bauser M, Hillig RC, Briem H, Eis K, Bader B, Nguyen D, Christ CD. Front Cover: Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRAS
G12C
(ChemMedChem 10/2020). ChemMedChem 2020. [DOI: 10.1002/cmdc.202000297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- Jérémie Mortier
- Bayer AGResearch & Development, Pharmaceuticals Müllerstrasse 178 13342 Berlin Germany
| | - Anders Friberg
- Bayer AGResearch & Development, Pharmaceuticals Müllerstrasse 178 13342 Berlin Germany
| | - Volker Badock
- Bayer AGResearch & Development, Pharmaceuticals Müllerstrasse 178 13342 Berlin Germany
| | - Dieter Moosmayer
- Bayer AGResearch & Development, Pharmaceuticals Müllerstrasse 178 13342 Berlin Germany
| | - Jens Schroeder
- Bayer AGResearch & Development, Pharmaceuticals Müllerstrasse 178 13342 Berlin Germany
| | - Patrick Steigemann
- Bayer AGResearch & Development, Pharmaceuticals Müllerstrasse 178 13342 Berlin Germany
| | - Franziska Siegel
- Bayer AGResearch & Development, Pharmaceuticals Müllerstrasse 178 13342 Berlin Germany
| | - Stefan Gradl
- Bayer AGResearch & Development, Pharmaceuticals Müllerstrasse 178 13342 Berlin Germany
| | - Marcus Bauser
- Bayer AGResearch & Development, Pharmaceuticals Müllerstrasse 178 13342 Berlin Germany
| | - Roman C. Hillig
- Bayer AGResearch & Development, Pharmaceuticals Müllerstrasse 178 13342 Berlin Germany
| | - Hans Briem
- Bayer AGResearch & Development, Pharmaceuticals Müllerstrasse 178 13342 Berlin Germany
| | - Knut Eis
- Bayer AGResearch & Development, Pharmaceuticals Müllerstrasse 178 13342 Berlin Germany
| | - Benjamin Bader
- Bayer AGResearch & Development, Pharmaceuticals Müllerstrasse 178 13342 Berlin Germany
| | - Duy Nguyen
- Bayer AGResearch & Development, Pharmaceuticals Müllerstrasse 178 13342 Berlin Germany
| | - Clara D. Christ
- Bayer AGResearch & Development, Pharmaceuticals Müllerstrasse 178 13342 Berlin Germany
| |
Collapse
|
16
|
Schulze VK, Klar U, Kosemund D, Wengner AM, Siemeister G, Stöckigt D, Neuhaus R, Lienau P, Bader B, Prechtl S, Holton SJ, Briem H, Marquardt T, Schirok H, Jautelat R, Bohlmann R, Nguyen D, Fernández-Montalván AE, Bömer U, Eberspaecher U, Brüning M, Döhr O, Raschke M, Kreft B, Mumberg D, Ziegelbauer K, Brands M, von Nussbaum F, Koppitz M. Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase. J Med Chem 2020; 63:8025-8042. [PMID: 32338514 DOI: 10.1021/acs.jmedchem.9b02035] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
Inhibition of monopolar spindle 1 (MPS1) kinase represents a novel approach to cancer treatment: instead of arresting the cell cycle in tumor cells, cells are driven into mitosis irrespective of DNA damage and unattached/misattached chromosomes, resulting in aneuploidy and cell death. Starting points for our optimization efforts with the goal to identify MPS1 inhibitors were two HTS hits from the distinct chemical series "triazolopyridines" and "imidazopyrazines". The major initial issue of the triazolopyridine series was the moderate potency of the HTS hits. The imidazopyrazine series displayed more than 10-fold higher potencies; however, in the early project phase, this series suffered from poor metabolic stability. Here, we outline the evolution of the two hit series to clinical candidates BAY 1161909 and BAY 1217389 and reveal how both clinical candidates bind to the ATP site of MPS1 kinase, while addressing different pockets utilizing different binding interactions, along with their synthesis and preclinical characterization in selected in vivo efficacy models.
Collapse
Affiliation(s)
- Volker K Schulze
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Ulrich Klar
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Dirk Kosemund
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Antje M Wengner
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Gerhard Siemeister
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Detlef Stöckigt
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Roland Neuhaus
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Philip Lienau
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Benjamin Bader
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Stefan Prechtl
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Simon J Holton
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Hans Briem
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Tobias Marquardt
- Research & Development, Pharmaceuticals, Bayer AG, 42113 Wuppertal, Germany
| | - Hartmut Schirok
- Research & Development, Pharmaceuticals, Bayer AG, 42113 Wuppertal, Germany
| | - Rolf Jautelat
- Research & Development, Pharmaceuticals, Bayer AG, 42113 Wuppertal, Germany
| | - Rolf Bohlmann
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Duy Nguyen
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | | | - Ulf Bömer
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Uwe Eberspaecher
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Michael Brüning
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Olaf Döhr
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Marian Raschke
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Bertolt Kreft
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Dominik Mumberg
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Karl Ziegelbauer
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Michael Brands
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Franz von Nussbaum
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| | - Marcus Koppitz
- Research & Development, Pharmaceuticals, Bayer AG, 13353 Berlin, Germany
| |
Collapse
|
17
|
Mortier J, Friberg A, Badock V, Moosmayer D, Schroeder J, Steigemann P, Siegel F, Gradl S, Bauser M, Hillig RC, Briem H, Eis K, Bader B, Nguyen D, Christ CD. Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRAS G12C. ChemMedChem 2020; 15:827-832. [PMID: 32237114 PMCID: PMC7318243 DOI: 10.1002/cmdc.201900727] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Indexed: 01/25/2023]
Abstract
Due to its frequent mutations in multiple lethal cancers, KRAS is one of the most-studied anticancer targets nowadays. Since the discovery of the druggable allosteric binding site containing a G12C mutation, KRASG12C has been the focus of attention in oncology research. We report here a computationally driven approach aimed at identifying novel and selective KRASG12C covalent inhibitors. The workflow involved initial enumeration of virtual molecules tailored for the KRAS allosteric binding site. Tools such as pharmacophore modeling, docking, and free-energy perturbations were deployed to prioritize the compounds with the best profiles. The synthesized naphthyridinone scaffold showed the ability to react with G12C and inhibit KRASG12C . Analogues were prepared to establish structure-activity relationships, while molecular dynamics simulations and crystallization of the inhibitor-KRASG12C complex highlighted an unprecedented binding mode.
Collapse
Affiliation(s)
- Jérémie Mortier
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13342, Berlin, Germany
| | - Anders Friberg
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13342, Berlin, Germany
| | - Volker Badock
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13342, Berlin, Germany
| | - Dieter Moosmayer
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13342, Berlin, Germany
| | - Jens Schroeder
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13342, Berlin, Germany
| | - Patrick Steigemann
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13342, Berlin, Germany
| | - Franziska Siegel
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13342, Berlin, Germany
| | - Stefan Gradl
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13342, Berlin, Germany
| | - Marcus Bauser
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13342, Berlin, Germany
| | - Roman C Hillig
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13342, Berlin, Germany
| | - Hans Briem
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13342, Berlin, Germany
| | - Knut Eis
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13342, Berlin, Germany
| | - Benjamin Bader
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13342, Berlin, Germany
| | - Duy Nguyen
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13342, Berlin, Germany
| | - Clara D Christ
- Bayer AG, Research & Development, Pharmaceuticals, Müllerstrasse 178, 13342, Berlin, Germany
| |
Collapse
|
18
|
Lefranc J, Schulze VK, Hillig RC, Briem H, Prinz F, Mengel A, Heinrich T, Balint J, Rengachari S, Irlbacher H, Stöckigt D, Bömer U, Bader B, Gradl SN, Nising CF, von Nussbaum F, Mumberg D, Panne D, Wengner AM. Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor. J Med Chem 2019; 63:601-612. [DOI: 10.1021/acs.jmedchem.9b01460] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Affiliation(s)
- Julien Lefranc
- Pharmaceuticals, Research and Development, Bayer AG, 13353 Berlin, Germany
| | | | | | - Hans Briem
- Pharmaceuticals, Research and Development, Bayer AG, 13353 Berlin, Germany
| | - Florian Prinz
- Pharmaceuticals, Research and Development, Bayer AG, 13353 Berlin, Germany
| | - Anne Mengel
- Pharmaceuticals, Research and Development, Bayer AG, 13353 Berlin, Germany
| | - Tobias Heinrich
- Pharmaceuticals, Research and Development, Bayer AG, 13353 Berlin, Germany
| | - Jozsef Balint
- ASCA GmbH (Angewandte Synthesechemie Adlershof), 12489 Berlin, Germany
| | - Srinivasan Rengachari
- Leicester Institute of Structural and Chemical Biology, Department of Molecular and Cell Biology, University of Leicester, Lancaster Road, LE1 7RH Leicester, U.K
| | - Horst Irlbacher
- Pharmaceuticals, Research and Development, Bayer AG, 13353 Berlin, Germany
| | - Detlef Stöckigt
- Pharmaceuticals, Research and Development, Bayer AG, 13353 Berlin, Germany
| | - Ulf Bömer
- Pharmaceuticals, Research and Development, Bayer AG, 13353 Berlin, Germany
| | - Benjamin Bader
- Pharmaceuticals, Research and Development, Bayer AG, 13353 Berlin, Germany
| | | | | | - Franz von Nussbaum
- Pharmaceuticals, Research and Development, Bayer AG, 13353 Berlin, Germany
| | - Dominik Mumberg
- Pharmaceuticals, Research and Development, Bayer AG, 13353 Berlin, Germany
| | - Daniel Panne
- Leicester Institute of Structural and Chemical Biology, Department of Molecular and Cell Biology, University of Leicester, Lancaster Road, LE1 7RH Leicester, U.K
- European Molecular Biology Laboratory, 38042 Grenoble, France
| | | |
Collapse
|
19
|
Abstract
Abstract
Mutants of RAS are major oncogenes and occur in many human cancers, but efforts to develop drugs that directly inhibit the corresponding constitutively active RAS proteins failed so far. We therefore focused on SOS1, the guanine nucleotide exchange factor (GEF) and activator of RAS. A combination of high-throughput and fragment screening resulted in the discovery of the first nanomolar SOS1 inhibitors, which effectively downregulate active RAS in tumor cells. The identification of novel potent and cellular active small molecule inhibitors will be presented which efficiently disrupt the interaction between KRAS and its exchange factor SOS1, a mode of action confirmed by a series of biophysical techniques. The binding sites, mode of action and selectivity were elucidated using crystal structures of KRASG12C–SOS1, SOS1 and SOS2. By preventing formation of the KRAS–SOS1 complex, these inhibitors block reloading of KRAS with GTP, leading to antiproliferative activity. Compound BAY-293 selectively inhibits the KRAS–SOS1 interaction with an IC50 of 21 nM and is a valuable chemical probe for future investigations. In cells with wild-type KRAS, we observed complete inhibition of the RAS–RAF–MEK–ERK pathway. In a mutant KRAS cell line, SOS1 inhibition resulted in a reduction of pERK activity by 50%. In preventing the reloading of with GTP the SOS-inhibitors strongly synergize with covalent inhibitors like ARS-853 or ARS-1620 targeting the mutant KRASG12C in its GDP-state. Together, the data indicate that inhibition of GEFs may represent a new viable approach for targeting RAS-driven tumors. Reference Hillig RC, et al. (2019) Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction. Proceedings of the National Academy of Sciences 116(7):2551-2560
Citation Format: Benjamin Bader. Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS-SOS1 interaction [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2019 Oct 26-30; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2019;18(12 Suppl):Abstract nr CN05-03. doi:10.1158/1535-7163.TARG-19-CN05-03
Collapse
|
20
|
Wengner AM, Siemeister G, Lücking U, Lefranc J, Wortmann L, Lienau P, Bader B, Bömer U, Moosmayer D, Eberspächer U, Golfier S, Schatz CA, Baumgart SJ, Haendler B, Lejeune P, Schlicker A, von Nussbaum F, Brands M, Ziegelbauer K, Mumberg D. The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models. Mol Cancer Ther 2019; 19:26-38. [PMID: 31582533 DOI: 10.1158/1535-7163.mct-19-0019] [Citation(s) in RCA: 109] [Impact Index Per Article: 21.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2019] [Revised: 07/05/2019] [Accepted: 09/27/2019] [Indexed: 11/16/2022]
Abstract
The DNA damage response (DDR) secures the integrity of the genome of eukaryotic cells. DDR deficiencies can promote tumorigenesis but concurrently may increase dependence on alternative repair pathways. The ataxia telangiectasia and Rad3-related (ATR) kinase plays a central role in the DDR by activating essential signaling pathways of DNA damage repair. Here, we studied the effect of the novel selective ATR kinase inhibitor BAY 1895344 on tumor cell growth and viability. Potent antiproliferative activity was demonstrated in a broad spectrum of human tumor cell lines. BAY 1895344 exhibited strong monotherapy efficacy in cancer xenograft models that carry DNA damage repair deficiencies. The combination of BAY 1895344 with DNA damage-inducing chemotherapy or external beam radiotherapy (EBRT) showed synergistic antitumor activity. Combination treatment with BAY 1895344 and DDR inhibitors achieved strong synergistic antiproliferative activity in vitro, and combined inhibition of ATR and PARP signaling using olaparib demonstrated synergistic antitumor activity in vivo Furthermore, the combination of BAY 1895344 with the novel, nonsteroidal androgen receptor antagonist darolutamide resulted in significantly improved antitumor efficacy compared with respective single-agent treatments in hormone-dependent prostate cancer, and addition of EBRT resulted in even further enhanced antitumor efficacy. Thus, the ATR inhibitor BAY 1895344 may provide new therapeutic options for the treatment of cancers with certain DDR deficiencies in monotherapy and in combination with DNA damage-inducing or DNA repair-compromising cancer therapies by improving their efficacy.
Collapse
Affiliation(s)
- Antje M Wengner
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany.
| | | | - Ulrich Lücking
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Julien Lefranc
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Lars Wortmann
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Philip Lienau
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Benjamin Bader
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Ulf Bömer
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Dieter Moosmayer
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Uwe Eberspächer
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Sven Golfier
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | | | - Simon J Baumgart
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Bernard Haendler
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Pascale Lejeune
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Andreas Schlicker
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | | | - Michael Brands
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Karl Ziegelbauer
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| | - Dominik Mumberg
- Bayer AG, Pharmaceuticals, Research and Development, Berlin, Germany
| |
Collapse
|
21
|
Bader B, Schuster T, Dickmann M. Managing people in hostile environments: lessons learned and new grounds in HR research. The International Journal of Human Resource Management 2019. [DOI: 10.1080/09585192.2018.1548499] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- Benjamin Bader
- Newcastle University Business School, Leadership, Work, and Organisation , Newcastle upon Tyne , UK
| | - Tassilo Schuster
- Faculty of Business Administration, Ludwig-Maximilians-Universität München , Munich , Germany
| | - Michael Dickmann
- International Human Resource Management, Cranfield School of Management, Cranfield University , UK
| |
Collapse
|
22
|
Bauser M, Giese A, Ellermann M, Guenther J, Eheim A, Bunse S, Neuhaus R, Weiske J, Quanz M, Glasauer A, Nowak-Reppel K, Bader B, Irlbacher H, Meyer H, Queisser N, Haegebarth A, Gorjanacz M, Tresaugues L, Ginman T, Rahm F, Andersson M, Ericsson U, Forsblom R, Lindstroem J, Silvander C, Vicklund J. Abstract 689: Identification and optimization of novel chemical matter via a structure-based approach resulting in a probe for MTH1. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-689] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Cancer cells can form reactive oxygen species (ROS) due to altered redox regulation that affect desoxynucleosides triphosphates (dNTP) in particular. 8-oxo-2'-deoxyguanosine-5'-triphosphate (8-oxo-dGTP) and 2-hydroxydeoxyadenosine-5'-triphosphate (2-OH-dATP) are the two most abundant oxidative nucleotide lesions in this respect. These undesired nucleoside triphosphates are sanitized by the hydrolase MTH1 (also known as NUDT1) in order to prevent their incorporation into replicating DNA. Sprint Bioscience created a series of drug-like, potent and selective MTH1 inhibitors using fragment-based drug discovery methods. In collaboration with Bayer, these inhibitors were extensively profiled, both in vitro and in vivo, to allow for the selection of a probe molecule with attractive properties for in vivo target validation studies. Herein, we would like to share novel chemical matter and it's binding to MTH1 in protein co-crystal structures. Furthermore, we describe the consecutive, stepwise structure-based optimization process. Extensive SAR elaboration clearly revealed the essential moieties for high potency and favorable ADME properties. We are able to report for the first time how we identified BAY-707 as a very potent and highly selective MTH1 inhibitor representing a potential probe to further evaluate the scope and limitations of MTH1 inhibition for therapeutic applications.
Citation Format: Marcus Bauser, Anja Giese, Manuel Ellermann, Judith Guenther, Ashley Eheim, Stefanie Bunse, Roland Neuhaus, Joerg Weiske, Maria Quanz, Andrea Glasauer, Katrin Nowak-Reppel, Benjamin Bader, Horst Irlbacher, Hanna Meyer, Nina Queisser, Andrea Haegebarth, Matyas Gorjanacz, Lionel Tresaugues, Tobias Ginman, Fredrik Rahm, Martin Andersson, Ulrica Ericsson, Rickard Forsblom, Johan Lindstroem, Camilla Silvander, Jenny Vicklund. Identification and optimization of novel chemical matter via a structure-based approach resulting in a probe for MTH1 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 689.
Collapse
|
23
|
Lemos C, Schulze VK, Bader B, Christ CD, Briem H, Politz O, Prinz F, Holton S, Heinrich T, Lefranc J, Lienau P, Scholz A, Nussbaum FV, Nising CF, Mumberg D, Bauser M, Hägebarth A. Abstract 5873: BAY-3827, a selective inhibitor of AMPK for the evaluation of the role of AMPK in Myc-dependent tumors. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-5873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The AMP-activated protein kinase (AMPK) is a sensor of the energy status in the cells, playing a key role in controlling their metabolism. For many years, AMPK was mainly perceived as a tumor suppressor in agreement with being a component of the LKB1 tumor suppressor cascade, which inhibits mTORC1. However, in the last few years, some studies suggested that AMPK might actually exert a pro-tumorigenic role in certain contexts. For instance, Liu and colleagues demonstrated that dysregulated MYC expression renders tumor cells sensitive to AMPK depletion (Liu et al, 2012. Nature). The authors showed that, due to their increased anabolism, MYC-dependent cells rely on AMPK to restore ATP levels and to prevent an energy crisis that results in apoptosis and cell death. Here we report the discovery of a new lead structure for the inhibition of AMPK by biochemical high throughput screening. The optimization of this lead structure towards potency and selectivity led to the probe compound BAY-3827 and the use of this tool compound to evaluate the therapeutic potential of AMPK inhibition in MYC-dependent tumors. To demonstrate a cellular effect of BAY-3827 an HRTF® assay (Homogeneous Time Resolved Fluorescence, cisbio) for phospho-Acetyl-CoA carboxylase (p-ACC, Ser79), a direct substrate of AMPK, was used. ACC phosphorylation was strongly inhibited by BAY-3827 in COLO 320DM and IMR-32 cells. However, despite its high potency, BAY-3827 failed to inhibit the proliferation of cells with dysregulated c-MYC or N-MYC. In conclusion, we have identified a potent and selective AMPK inhibitor. Despite demonstrated inhibition of AMPK kinase activity, BAY-3827 treatment did not translate into antiproliferative activity in MYC-dependent cells. While we could not confirm our initial hypothesis, one might speculate that inhibition of AMPK might be of therapeutic utility in other biological contexts. Therefore, the availability of potent and selective inhibitors, as described here, will contribute to further insight into the potential of AMPK inhibition as a therapeutic target in cancer.
Citation Format: Clara Lemos, Volker K. Schulze, Benjamin Bader, Clara D. Christ, Hans Briem, Oliver Politz, Florian Prinz, Simon Holton, Tobias Heinrich, Julien Lefranc, Philip Lienau, Arne Scholz, Franz von Nussbaum, Carl Friedrich Nising, Dominik Mumberg, Marcus Bauser, Andrea Hägebarth. BAY-3827, a selective inhibitor of AMPK for the evaluation of the role of AMPK in Myc-dependent tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5873.
Collapse
|
24
|
Liu J, Heinsen H, Grinberg LT, Alho E, Amaro E, Pasqualucci CA, Rüb U, Seidel K, den Dunnen W, Arzberger T, Schmitz C, Kiessling MC, Bader B, Danek A. Pathoarchitectonics of the cerebral cortex in chorea-acanthocytosis and Huntington's disease. Neuropathol Appl Neurobiol 2018; 45:230-243. [PMID: 29722054 DOI: 10.1111/nan.12495] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2017] [Accepted: 02/27/2018] [Indexed: 11/29/2022]
Abstract
AIMS Quantitative estimation of cortical neurone loss in cases with chorea-acanthocytosis (ChAc) and its impact on laminar composition. METHODS We used unbiased stereological tools to estimate the degree of cortical pathology in serial gallocyanin-stained brain sections through the complete hemispheres of three subjects with genetically verified ChAc and a range of disease durations. We compared these results with our previous data of five Huntington's disease (HD) and five control cases. Pathoarchitectonic changes were exemplarily documented in TE1 of a 61-year-old female HD-, a 60-year-old female control case, and ChAc3. RESULTS Macroscopically, the cortical volume of our ChAc cases (ChAc1-3) remained close to normal. However, the average number of neurones was reduced by 46% in ChAc and by 33% in HD (P = 0.03 for ChAc & HD vs. controls; P = 0.64 for ChAc vs. HD). Terminal HD cases featured selective laminar neurone loss with pallor of layers III, V and VIa, a high density of small, pale, closely packed radial fibres in deep cortical layers VI and V, shrinkage, and chromophilia of subcortical white matter. In ChAc, pronounced diffuse astrogliosis blurred the laminar borders, thus masking the complete and partial loss of pyramidal cells in layer IIIc and of neurones in layers III, V and VI. CONCLUSION ChAc is a neurodegenerative disease with distinct cortical neurodegeneration. The hypertrophy of the peripheral neuropil space of minicolumns with coarse vertical striation was characteristic of ChAc. The role of astroglia in the pathogenesis of this disorder remains to be elucidated.
Collapse
Affiliation(s)
- J Liu
- Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.,Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, München, Germany
| | - H Heinsen
- Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital Würzburg, Würzburg, Germany.,Ageing Brain Study Group, Department of Pathology, University of São Paulo Medical School, São Paulo, Brazil
| | - L T Grinberg
- Department of Neurology, University of California, San Francisco, San Francisco, CA, USA
| | - E Alho
- Praça Amadeu Amaral, São Paulo, Brazil
| | - E Amaro
- Department of Radiology, University of São Paulo Medical School, São Paulo, Brazil
| | - C A Pasqualucci
- Ageing Brain Study Group, Department of Pathology, University of São Paulo Medical School, São Paulo, Brazil
| | - U Rüb
- Experimental Neurobiology (Anatomical Institute II), Goethe-University, Frankfurt/Main, Germany
| | - K Seidel
- Experimental Neurobiology (Anatomical Institute II), Goethe-University, Frankfurt/Main, Germany.,Anatomy & Cell Biology, Medical Faculty, Anatomical Institute, University of Bonn, Bonn, Germany
| | - W den Dunnen
- Department of Pathology and Medical Biology, University Medical Center Groningen University of Groningen, Groningen, The Netherlands
| | - T Arzberger
- Center for Neuropathology and Prion Research, Ludwig-Maximilians-University Munich, Munich, Germany.,Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University Munich, Munich, Germany
| | - C Schmitz
- Department of Neuroanatomy, Ludwig-Maximilians-Universität München, Munich, Germany
| | - M C Kiessling
- Department of Neuroanatomy, Ludwig-Maximilians-Universität München, Munich, Germany
| | - B Bader
- Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, München, Germany.,Clienia Privatklinik für Psychiatrie und Psychotherapie, Oetwil am See, Switzerland
| | - A Danek
- Neurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität München, München, Germany
| |
Collapse
|
25
|
|
26
|
Breitenmoser A, Bader B, Berg N. Why does repatriate career success vary? An empirical investigation from both traditional and protean career perspectives. Hum Resour Manage 2017. [DOI: 10.1002/hrm.21888] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
27
|
Ellermann M, Eheim A, Rahm F, Viklund J, Guenther J, Andersson M, Ericsson U, Forsblom R, Ginman T, Lindström J, Silvander C, Trésaugues L, Giese A, Bunse S, Neuhaus R, Weiske J, Quanz M, Glasauer A, Nowak-Reppel K, Bader B, Irlbacher H, Meyer H, Queisser N, Bauser M, Haegebarth A, Gorjánácz M. Novel Class of Potent and Cellularly Active Inhibitors Devalidates MTH1 as Broad-Spectrum Cancer Target. ACS Chem Biol 2017; 12:1986-1992. [PMID: 28679043 DOI: 10.1021/acschembio.7b00370] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
MTH1 is a hydrolase responsible for sanitization of oxidized purine nucleoside triphosphates to prevent their incorporation into replicating DNA. Early tool compounds published in the literature inhibited the enzymatic activity of MTH1 and subsequently induced cancer cell death; however recent studies have questioned the reported link between these two events. Therefore, it is important to validate MTH1 as a cancer dependency with high quality chemical probes. Here, we present BAY-707, a substrate-competitive, highly potent and selective inhibitor of MTH1, chemically distinct compared to those previously published. Despite superior cellular target engagement and pharmacokinetic properties, inhibition of MTH1 with BAY-707 resulted in a clear lack of in vitro or in vivo anticancer efficacy either in mono- or in combination therapies. Therefore, we conclude that MTH1 is dispensable for cancer cell survival.
Collapse
|
28
|
Puck J, Hödl MK, Filatotchev I, Wolff HG, Bader B. Ownership mode, cultural distance, and the extent of parent firms’ strategic control over subsidiaries in the PRC. Asia Pac J Manag 2016. [DOI: 10.1007/s10490-016-9471-2] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
29
|
Held K, Bader B. The influence of images on organizational attractiveness: comparing Chinese, Russian and US companies in Germany. The International Journal of Human Resource Management 2016. [DOI: 10.1080/09585192.2016.1173085] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Katrin Held
- Department of Strategic Management, University of Hamburg, Hamburg, Germany
| | - Benjamin Bader
- Institute of Corporate Development, Leuphana University of Lüneburg, Lüneburg, Germany
| |
Collapse
|
30
|
Wengner AM, Siemeister G, Koppitz M, Schulze V, Kosemund D, Klar U, Stoeckigt D, Neuhaus R, Lienau P, Bader B, Prechtl S, Raschke M, Frisk AL, von Ahsen O, Michels M, Kreft B, von Nussbaum F, Brands M, Mumberg D, Ziegelbauer K. Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity. Mol Cancer Ther 2016; 15:583-92. [PMID: 26832791 DOI: 10.1158/1535-7163.mct-15-0500] [Citation(s) in RCA: 74] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2015] [Accepted: 01/04/2016] [Indexed: 11/16/2022]
Abstract
Monopolar spindle 1 (Mps1) has been shown to function as the key kinase that activates the spindle assembly checkpoint (SAC) to secure proper distribution of chromosomes to daughter cells. Here, we report the structure and functional characterization of two novel selective Mps1 inhibitors, BAY 1161909 and BAY 1217389, derived from structurally distinct chemical classes. BAY 1161909 and BAY 1217389 inhibited Mps1 kinase activity with IC50 values below 10 nmol/L while showing an excellent selectivity profile. In cellular mechanistic assays, both Mps1 inhibitors abrogated nocodazole-induced SAC activity and induced premature exit from mitosis ("mitotic breakthrough"), resulting in multinuclearity and tumor cell death. Both compounds efficiently inhibited tumor cell proliferation in vitro (IC50 nmol/L range). In vivo, BAY 1161909 and BAY 1217389 achieved moderate efficacy in monotherapy in tumor xenograft studies. However, in line with its unique mode of action, when combined with paclitaxel, low doses of Mps1 inhibitor reduced paclitaxel-induced mitotic arrest by the weakening of SAC activity. As a result, combination therapy strongly improved efficacy over paclitaxel or Mps1 inhibitor monotreatment at the respective MTDs in a broad range of xenograft models, including those showing acquired or intrinsic paclitaxel resistance. Both Mps1 inhibitors showed good tolerability without adding toxicity to paclitaxel monotherapy. These preclinical findings validate the innovative concept of SAC abrogation for cancer therapy and justify clinical proof-of-concept studies evaluating the Mps1 inhibitors BAY 1161909 and BAY 1217389 in combination with antimitotic cancer drugs to enhance their efficacy and potentially overcome resistance. Mol Cancer Ther; 15(4); 583-92. ©2016 AACR.
Collapse
Affiliation(s)
| | | | | | | | | | - Ulrich Klar
- Bayer Pharma AG, Drug Discovery, Berlin, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Wengner AM, Siemeister G, Koppitz M, Schulze V, Kosemund D, Klar U, Stoeckigt D, Neuhaus R, Lienau P, Bader B, Prechtl S, Doehr O, Raschke M, von Ahsen O, Elbi C, Bruns I, Michels M, Kreft B, von Nussbaum F, Brands M, Mumberg D, Ziegelbauer K. Abstract 3090: Novel Mps1 kinase inhibitors with potent anti-tumor activity. Mol Cell Biol 2015. [DOI: 10.1158/1538-7445.am2015-3090] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
32
|
Schuster T, Bader B. Corporate masterminds – executive management teams in focus. Team Performance Management 2015. [DOI: 10.1108/tpm-03-2015-0016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
33
|
Bader B, Schuster T, Dickmann M. Special issue of International Journal of Human Resource Management: Danger and risk as challenges for HRM: how to manage people in hostile environments. The International Journal of Human Resource Management 2015. [DOI: 10.1080/09585192.2015.1038116] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
34
|
Bader B, Schuster T, Dickmann M. Special issue ofInternational Journal of Human Resource Management: Danger and risk as challenges for HRM: how to manage people in hostile environments. The International Journal of Human Resource Management 2015. [DOI: 10.1080/09585192.2015.1019256] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
35
|
Bader B, Schuster T. Expatriate Social Networks in Terrorism-Endangered Countries: An Empirical Analysis in Afghanistan, India, Pakistan, and Saudi Arabia. Journal of International Management 2015. [DOI: 10.1016/j.intman.2014.09.004] [Citation(s) in RCA: 59] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
36
|
Bader B. The power of support in high-risk countries: compensation and social support as antecedents of expatriate work attitudes. The International Journal of Human Resource Management 2014. [DOI: 10.1080/09585192.2014.962071] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
37
|
Schulze J, Moosmayer D, Weiske J, Fernández-Montalván A, Herbst C, Jung M, Haendler B, Bader B. Cell-Based Protein Stabilization Assays for the Detection of Interactions between Small-Molecule Inhibitors and BRD4. ACTA ACUST UNITED AC 2014; 20:180-9. [DOI: 10.1177/1087057114552398] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Bromodomain protein 4 (BRD4), a member of the bromodomain and extra-terminal (BET) protein family, acts as a central element in transcriptional elongation and plays essential roles in cell proliferation. Inhibition of BRD4 binding to acetylated histone tails via its two bromodomains, BD1 and BD2, with small-molecule inhibitors has been shown to be a valid strategy to prevent cancer growth. We have evaluated and established two novel assays that quantify the interaction of transfected BRD4 BD1 with chemical inhibitors inside cultured cells. Both methods are based on the principle of ligand-induced protein stabilization by which the binding of a small-molecule inhibitor stabilizes intracellular BRD4 BD1 and protects it from proteolytic degradation. We demonstrate the universal character of this principle by using two orthogonal, highly sensitive detection technologies for the quantification of BRD4 BD1 levels in cellular lysates: enzyme fragment complementation and time-resolved fluorescence resonance energy transfer (TR-FRET). Upon optimization of both assays to a miniaturized high-throughput format, the methods were validated by testing a set of small-molecule BET inhibitors and comparing the results with those from a cell-free binding assay and a biophysical thermal shift assay. In addition, point mutations were introduced into BRD4 BD1, and the corresponding mutants were characterized in the TR-FRET stabilization assay.
Collapse
Affiliation(s)
- Jessica Schulze
- Lead Discovery/Screening, Global Drug Discovery, Bayer Healthcare, Berlin, Germany
- Max Planck Institute of Colloids and Interfaces, 14476 Potsdam, Germany
| | - Dieter Moosmayer
- Lead Discovery/Protein Technologies, Global Drug Discovery, Bayer Healthcare, Berlin, Germany
| | - Joerg Weiske
- Lead Discovery/Protein Technologies, Global Drug Discovery, Bayer Healthcare, Berlin, Germany
| | | | - Christopher Herbst
- Lead Discovery/Screening, Global Drug Discovery, Bayer Healthcare, Berlin, Germany
| | - Marie Jung
- Therapeutic Research Group Oncology/Gynecological Therapies, Global Drug Discovery, Bayer Healthcare, Berlin, Germany
- Institute of Chemistry and Biochemistry, Free University, Berlin, Germany
| | - Bernard Haendler
- Therapeutic Research Group Oncology/Gynecological Therapies, Global Drug Discovery, Bayer Healthcare, Berlin, Germany
| | - Benjamin Bader
- Lead Discovery/Screening, Global Drug Discovery, Bayer Healthcare, Berlin, Germany
| |
Collapse
|
38
|
Jung M, Philpott M, Müller S, Schulze J, Badock V, Eberspächer U, Moosmayer D, Bader B, Schmees N, Fernández-Montalván A, Haendler B. Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1. J Biol Chem 2014; 289:9304-19. [PMID: 24497639 PMCID: PMC3979416 DOI: 10.1074/jbc.m113.523019] [Citation(s) in RCA: 104] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Bromodomain protein 4 (BRD4) is a member of the bromodomain and extra-terminal domain (BET) protein family. It binds to acetylated histone tails via its tandem bromodomains BD1 and BD2 and forms a complex with the positive transcription elongation factor b, which controls phosphorylation of RNA polymerase II, ultimately leading to stimulation of transcription elongation. An essential role of BRD4 in cell proliferation and cancer growth has been reported in several recent studies. We analyzed the binding of BRD4 BD1 and BD2 to different partners and showed that the strongest interactions took place with di- and tetra-acetylated peptides derived from the histone 4 N-terminal tail. We also found that several histone 4 residues neighboring the acetylated lysines significantly influenced binding. We generated 10 different BRD4 BD1 mutants and analyzed their affinities to acetylated histone tails and to the BET inhibitor JQ1 using several complementary biochemical and biophysical methods. The impact of these mutations was confirmed in a cellular environment. Altogether, the results show that Trp-81, Tyr-97, Asn-140, and Met-149 play similarly important roles in the recognition of acetylated histones and JQ1. Pro-82, Leu-94, Asp-145, and Ile-146 have a more differentiated role, suggesting that different kinds of interactions take place and that resistance mutations compatible with BRD4 function are possible. Our study extends the knowledge on the contribution of individual BRD4 amino acids to histone and JQ1 binding and may help in the design of new BET antagonists with improved pharmacological properties.
Collapse
Affiliation(s)
- Marie Jung
- From the Global Drug Discovery, Bayer HealthCare, 13353 Berlin, Germany
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Bader B, Berg N. The influence of terrorism on expatriate performance: a conceptual approach. The International Journal of Human Resource Management 2013. [DOI: 10.1080/09585192.2013.814702] [Citation(s) in RCA: 47] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
40
|
Bader B, Berg N. An Empirical Investigation of Terrorism-induced Stress on Expatriate Attitudes and Performance. Journal of International Management 2013. [DOI: 10.1016/j.intman.2013.01.003] [Citation(s) in RCA: 76] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
41
|
Wehrman T, Nguyen M, Feng W, Bader B. EphB4 cellular kinase activity assayed using an enzymatic protein interaction system. Assay Drug Dev Technol 2013; 11:237-43. [PMID: 23557019 DOI: 10.1089/adt.2012.490] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
Receptor tyrosine kinases (RTKs) are important players in various cellular processes, including proliferation, migration, metabolism, and neuronal development. EphB4 RTK is essential for the development of a functional arterial-venous network in embryonic and adult neoangiogenesis. To develop novel inhibitors of EphB4 that might have applications in severe diseases like cancer and retinopathies, assays need to be in place that resemble, in a most physiological fashion, the activation and downstream function of the kinase. In addition, such assays need to be amenable to high-throughput screening to serve efficiently the modern drug discovery processes in the pharmaceutical industry. The authors have developed an enzyme fragment complementation assay that measures the interaction of a downstream docking protein to the activated and phosphorylated full-length EphB4 kinase in cells. The assay is specific, robust, and amenable to miniaturization and high-throughput screening. It covers most steps in the activation process of EphB4, including ligand binding, autophosphorylation, and docking of a downstream interactor. This assay format can be transferred to other RTKs and adds an important cell-based kinase assay option to researchers in the field.
Collapse
Affiliation(s)
- Tom Wehrman
- DiscoveRx Corporation, Fremont, California 94538, USA.
| | | | | | | |
Collapse
|
42
|
Williamson J, Fiddes B, Chan J, Mohiddin S, Danek A, Bader B, Earley M, Page S, Radunovic A. A PATIENT WITH CHOREA-ACANTHOCYTOSIS AND DILATED CARDIOMYOPATHY. J Neurol Neurosurg Psychiatry 2012. [DOI: 10.1136/jnnp-2012-304200a.55] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
43
|
Paradas Lopez C, Cabrera Serrano M, Rivas Infante E, Morales JM, Marquez C, Bader B, Mir P. Neuromuscular Involvement in Choreoacanthocytosis (P07.204). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.p07.204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
44
|
Bader B, Liu J, Kretzschmar H, Danek A. DNA-Datenbank seltener Bewegungsstörungen. KLIN NEUROPHYSIOL 2011. [DOI: 10.1055/s-0031-1272685] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
45
|
Langer G, Bader B, Meoli L, Isensee J, Delbeck M, Noppinger PR, Otto C. A critical review of fundamental controversies in the field of GPR30 research. Steroids 2010; 75:603-10. [PMID: 20034504 DOI: 10.1016/j.steroids.2009.12.006] [Citation(s) in RCA: 125] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/31/2009] [Revised: 11/25/2009] [Accepted: 12/12/2009] [Indexed: 01/01/2023]
Abstract
The female sex hormone estradiol plays an important role in reproduction, mammary gland development, bone turnover, metabolism, and cardiovascular function. The effects of estradiol are mediated by two classical nuclear receptors, estrogen receptor alpha (ERalpha) and estrogen receptor beta (ERbeta). In 2005, G-protein-coupled receptor 30 (GPR30) was claimed to act as a non-classical estrogen receptor that was also activated by the ERalpha and ERbeta antagonists tamoxifen and fulvestrant (ICI 182780). Despite many conflicting results regarding the potential role of GPR30 as an estrogen receptor, the official nomenclature was changed to GPER (G-protein-coupled estrogen receptor). This review revisits the inconsistencies that still exist in the literature and focuses on selected publications that basically address the following two questions: what is the evidence for and against the hypothesis that GPR30 acts as an estrogen receptor? What is the potential in vivo role of GPR30? Thus, in the first part we focus on conflicting results from in vitro studies analysing the subcellular localization of GPR30, its ability to bind (or not to bind) estradiol and to signal (or not to signal) in response to estradiol. In the second part, we discuss the strengths and limitations of four available GPR30 mouse models. We elucidate the potential impact of different targeting strategies on phenotypic diversity.
Collapse
Affiliation(s)
- Gernot Langer
- Lead Generation & Optimization, Screening Berlin, Bayer Schering Pharma AG, 13342 Berlin, Germany
| | | | | | | | | | | | | |
Collapse
|
46
|
Janati AB, Jalili B, Scheid R, Bader B. DEVELOPMENT OF MESIAL TEMPORAL LOBE EPILEPSY IN CHOREA-ACANTHOCYTOSIS. Neurology 2010; 74:1747; author reply 1747. [DOI: 10.1212/wnl.0b013e3181e02e49] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
47
|
|
48
|
Hilal T, Puetter V, Otto C, Parczyk K, Bader B. A dual estrogen receptor TR-FRET assay for simultaneous measurement of steroid site binding and coactivator recruitment. ACTA ACUST UNITED AC 2010; 15:268-78. [PMID: 20150592 DOI: 10.1177/1087057109359196] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The human estrogen receptors (hER) are members of the nuclear hormone receptor (NHR) superfamily and represent important drug targets for the pharmaceutical industry. Initially, ligand binding assays were used to identify novel ligands using receptors purified from native tissues. With the advent of molecular cloning techniques, cell-based transactivation assays have been the gold standard for many years of drug discovery. With the elucidation of the structural mechanisms underlying the activation of NHRs, cell-free assays with purified receptors have become important tools to directly assess different binding sites (e.g., the hormone binding site or the cofactor binding site). The available cell-free assays have so far facilitated the study of one binding site at a time. With the introduction of Terbium (Tb(3+))-based time-resolved fluorescence energy transfer (TR-FRET), it has become possible to measure 2 different interactions within 1 test tube in parallel. The authors have applied this technology to develop a dual readout system for the simultaneous monitoring of steroid hormone site binding and cofactor peptide recruitment. They took advantage of a commercially available fluorescent tracer as an indicator for classical steroid site binding and designed a novel peptide derived from the peroxisome proliferator-activated receptor gamma coactivator-1a (PGC1a) as an indicator for functional agonistic behavior of a test compound. The established assay is able to differentiate between agonists, antagonists, partial agonists, and compounds binding to the cofactor recruitment site. The IC(50) values obtained for a number of reference compounds in the multiplexed assay are in concordance with published data. The simple 1-step mix-and-measure protocol gives excellent quality and robustness and can be miniaturized to 5-microL volume.
Collapse
Affiliation(s)
- Tarek Hilal
- Lead Generation and Optimization, Screening, Bayer Schering Pharma AG, Muellerstr. 178, 13342 Berlin, Germany
| | | | | | | | | |
Collapse
|
49
|
Affiliation(s)
- R Scheid
- Max Planck Institute for Human Cognitive and Brain Sciences, Stephanstrasse 1A, 04103 Leipzig, Germany.
| | | | | | | | | |
Collapse
|
50
|
Kassem G, Al Tabash N, Bader B, Mohe-eldin D. P416 Secondary ectopic omental conjoined twin pregnancy: case report and review of literature. Int J Gynaecol Obstet 2009. [DOI: 10.1016/s0020-7292(09)61908-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|